Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was EUR 28.28 million compared to EUR 2.88 million a year ago. Net loss was EUR 375.78 million compared to EUR 277.52 million a year ago. Basic loss per share from continuing operations was EUR 6.7 compared to EUR 5.13 a year ago.